Eye Know O.D. logo
Register
Email Address: *
First Name: *
Last Name: *
Title:
Profession:
Password: *
Confirm Password: *

By clicking “Register” you are agreeing to the Terms and Conditions and Privacy Policy.

Ryzumvi®

phentolamine 0.75%
ophthalmic solution
Misc.
[ relatively non-selective alpha-1 and alpha-2 adrenergic antagonist]
Indication

Indication

Treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.
Mechanism of Action

Mechanism of Action

Ryzumvi is a relatively non-selective alpha-1 and alpha-2 adrenergic antagonist. Dilation of the pupil is primarily controlled by the radial iris dilator muscles surrounding the pupil; these muscles are activated by the alpha-1 adrenergic receptors. Phentolamine reversibly binds to these receptors on the iris dilator muscle, thereby reducing pupil diameter. Phentolamine directly antagonizes the mydriatic effect of an α-1 adrenergic agonist, and indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter muscle.
Common quantities available

Available Quantities

30 single use 0.31 mL vials
Dosage

Dosage/Instructions

• Adults and pediatric patients aged 12 years and older: Instill 1 to 2 drops in each dilated eye following the completion of the ophthalmic examination or procedure to reverse mydriasis. (2) • Pediatric patients aged 3 to 11 years: Instill 1 drop in each dilated eye following the completion of the ophthalmic examination or procedure to reverse mydriasis.
Pregnancy & Nursing Data

Pregnancy & Nursing

There are no available data with Ryzumvi administration in pregnant women to inform a drug-associated risk. In animal toxicology studies, when phentolamine was administered orally to pregnant mice and rats during the period of organogenesis skeletal immaturity and decreased growth was observed in the offspring at doses at least 24-times the recommended clinical dose. Additionally, a lower rate of implantation was seen in pregnant rats treated with phentolamine administered at least 60- times the recommended clinical dose. No malformations or embryofetal deaths were observed in the offspring of pregnant mice, rats, and rabbits administered phentolamine during the period of organogenesis at doses of at least 24-, 60-, and 20-times, respectively, the recommended clinical dose. There is no information regarding the presence of phentolamine in human milk, the effects on the breastfed infants, or the effects on milk production during lactation to inform risk of phentolamine ophthalmic solution 0.75% to an infant.
Pediatric Use

Pediatric Use

≥3 years
Warnings Tab

Contraindications, side effects, etc.

Uveitis: Ryzumvi is not recommended to be used in patients with active ocular inflammation.